The objective of this study was to describe the exposure to non-corticosteroid treatments in adult primary @entity3039 ( @entity3039 ) @entity1 before the chronic phase at a nationwide level. Study population is derived from the 2009-2011 cohort of the French Adult Immune @entity882 : a French pHarmacoepidemiological study (FAITH, no. ENCEPP 4574). The FAITH cohort includes all incident and persistent or chronic adult primary @entity3039 @entity1 treated in France. It was built through the nationwide French health insurance database, called SNIIRAM. For the present study, we included FAITH @entity1 who were followed by at least 12months and who had at least one exposure to a non-corticosteroid treatment before the @entity3039 chronic phase. Exposure to non-corticosteroid treatments was searched through in- and out-hospital dispensing. Predictors of the choice among first-line non-corticosteroid treatments (rituximab, splenectomy or other drugs) were studied using a multinomial regression. The study population included 443 @entity1 . Non-corticosteroid treatments used in more than 10% of the @entity1 at any time before the chronic phase were: rituximab (57.8%), splenectomy (22.1%), TPO-RAs (16.8%), repeated intravenous immunoglobulin (IVIg) courses (15.0%), danazol (14.4%) and dapsone (10.8%). Rituximab was the most used first-line non-corticosteroid treatment (45.4%). TPO-RAs and dapsone were more frequently used after 65years of age (respectively, 24.8% versus 12.8%, p=0.01 and 17.6% versus 7.2%, p=0.0008), unlike splenectomy (16.4% versus 25.2%, p=0.03). Age over 65years was the sole independent predictor of first-line non-corticosteroid treatment choice. In conclusion, rituximab was the leading non-corticosteroid treatment used before the chronic phase. TPO-RAs were mainly used in accordance with their labeling. IVIgs were consistently used as a chronic non-corticosteroid treatment.

Exposure to non-corticosteroid treatments in adult primary XXXX before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3039 :: ('MESH:D016553', 'Disease') :: ['ITP', 'immune thrombocytopenia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['Thrombocytopenia']
@entity3039 :: (MESH:D016553,Disease) :: ['immune thrombocytopenia']
